Phenocell

Phenocell is a biotechnology company founded in 2013 based in France. The company specializes in in vitro R&D solutions for the pharmaceutical and dermo-cosmetic industry. Using Nobel-prize winning technology of cellular reprogramming, Phenocell creates foot-print free, feeder-free, hiPSC that are further differentiated into somatic cells and amenable to 3D projects. They are known for large batches of qualified cells used in unique phenotypic assays to repurpose existing drugs or discover new compounds. Phenocell's areas of expertise include the production of human skin cells such as sebocytes, melanocytes, and keratinocytes, as well as human retinal cells like retinal pigment epithelium cells. They also apply iPSC-derived somatic cells to phenotypic assays. The company positions itself as a designated partner for open innovation projects and emphasizes its role in research and drug discovery. Phenocell offers detailed information about its products and services on www.phenocell.com. Currently, there is no public information available regarding the last investment and the involved investors.